In the next few days I will be migrating the blog from blogger to wordpress.
Your Brain In Space
16 hours ago
So...this is to chronicle my study of Medicine and how everything in life is affected by it.
“A mind map is a diagram used to represent words, ideas, tasks, or other items linked to and arranged around a central key word or idea…Mind maps are used to generate, visualize, structure, and classify ideas, and as an aid to studying and organizing information, solving problems, making decisions, and writing.”
Image Courtesy : Rana2030 |
“Yet I find myself disagreeing with Justice Katju's broad swipe. It is easy to tar the entire media with one broad brush of criticism. But not all journalists are the same, just as not all judges are the same. There are many journalists who are doing exactly what Justice Katju thinks journalists should be doing, and they are not necessarily all high-profile.”
Carry your opponent's proposition beyond its natural limits; exaggerate it. The more general your opponent's statement becomes, the more objections you can find against it. The more restricted and narrow his or her propositions remain, the easier they are to defend by him or her.
Another plan is to confuse the issue by changing your opponent's words or what he or she seeks to prove.
"I am not saying that there are no good journalists at all in the media. There are many excellent journalists. P. Sainath is one of them, whose name should be written in letters of gold in the history of Indian journalism."
“It also needs to be said that the media have made a lot more positive contribution than they are given credit for. Much of the corruption that has come to light over the last one year, all the scams that are currently churning the Indian polity, would have gone unnoticed had it not been for exposés by news organisations.”
“But it is also expected of the chairman of the Press Council to separate himself from Everyman, and take a more nuanced view of the complex terrain before him.”
Image courtesy: The Hindu |
Parameter
|
Outcome
|
Weight Loss
|
Weighted mean difference in mean weight change between behavioral intervention
and control group is -3.01 kg 95% CI (-4.02 to -2.01) at 12 to 18 months.
Behavioral interventions lasting longer continued to show weight loss. Weight
los was maintained up to a year following active intervention phase.
|
Mortality
|
No difference in death rate but limited by small number of
trials.
|
Cardiovascular disease
|
No difference in CVD events or CVD related deaths in 3
large good quality trials
|
Hospitalization
|
No difference, limited by low hospitalization rate.
|
Health related quality
of life/depression
|
No difference in depression, small favorable change of
health related quality of life with weight loss
|
Incidence of
diabetes mellitus
|
Weight loss of 4 to 7 kg reduced diabetes incidence by 50%
or more over 2 to 3 years.
|
Glucose tolerance
|
Mean decrease in glucose level = 0.30 mmol/L (5.4 mg/dL)
|
Lipids
|
Weighted mean difference in LDL cholesterol level between treatment
and control group = -4.94 mg/dL 95%CI (-7.32 to -2.56)
|
Blood pressure
|
Weighted mean difference in mean change in blood pressure between
treatment and control group = -2.48 mmHg 95%CI (-3.25 to -1.71)
|
Waist circumference
|
-2.7 cm 95%CI( -4.1 to 1.4)
|
Adverse effects
|
None
|
Parameter
|
Outcome
|
Weight Loss
|
Weighted mean difference between behavioral intervention
and control group is -2.98 kg 95% CI (-3.92 to -2.05).
|
Mortality
|
There were 4 studies which reported this outcome. Each
study reported 1 death in in the orlistat group, but no clear relationship
with treatment.
|
Cardiovascular disease
|
Not reported.
|
Hospitalization
|
Not reported.
|
Health related quality
of life/depression
|
No difference in depression, Orlistat had greater satisfaction
with treatment, less overweight distress and improvement in the vitality
subscale of SF – 36.
|
Incidence of
diabetes mellitus
|
Decreased incidence by 9-10% but concerns regarding
generalizability and reliability.
|
Glucose tolerance
|
Mean decrease in glucose level = 0.31 mmol/L (5.5 mg/dL).
Glucose reductions are greater in orlistat than placebo possibly because they
were conducted in diabetic patients.
|
Lipids
|
Weighted mean difference in LDL cholesterol level between treatment
and control group = -11.37 mg/dL 95%CI (-15.75 to -7.00)
|
Blood pressure
|
Weighted mean difference in mean change in blood pressure between
treatment and control group = -2.04 mmHg 95%CI (-2.97 to -1.11)
|
Waist circumference
|
-2.3 cm 95%CI( -3.6 to -0.9)
|
Adverse effects
|
Gastrointestinal symptoms of mild to moderate intensity
which resolves spontaneously, liver injury, vitamin E and K deficiency,
increased incidence of hypoglycemia.
|
Hazard ratio (95% CI) Adjusted Cox proportional hazards
regression analysis
|
Hazard ratio (95% CI) Adjusted marginal structural models
analysis
|
|
Any Hormonal Contraception
|
1.98 (1.06-3.68)*
|
1.84 (0.98-3.47)
|
Injectable
|
2.05 (1.04-4.04)*
|
2.19 (1.01-4.74)*
|
Oral
|
1.80 (0.55-5.82)
|
1.63 (0.47-5.66)
|
*significant
|
Hazard ratio (95% CI) Adjusted Cox proportional hazards
regression analysis
|
Hazard ratio (95% CI) Adjusted marginal structural models
analysis
|
|
Any Hormonal Contraception
|
1.97 (1.12-3.45)*
|
2.05 (1.12-3.74)*
|
Injectable
|
1.95 (1.06-3.58)*
|
3.01 (1.47-6.16)*
|
Oral
|
2.09 (0.75-5.84)
|
2.35 (0.79-6.95)
|
*significant
|
© Copyright 2009 | Medicine...Life | Theme by Columbia, MO Web Design | Bloggerized by Dhampire | All Rights Reserved